About US
Contact us
-
Ex-Allergan chief Pyott sells off San Juan mansion for $5MFormerAllerganChairman and CEODavid Pyottfound himself out of a job whenActavissnapped up his company. He walked away with quite a golden parachute, however--$534 million, says theOrange County Regist2015/6/25
-
AbbVie's hep C cocktail delivers 100% cure rate in genotype 1b nicheAbbVie knows it has to press its case forViekira Pakif it's going to get--and keep--a sizable share of thehepatitis Cmarket. Today, it unveiled some new data that could help it do just that. Viekira2015/6/25
-
ASCO proposes cancer drug scorecard, with some scary examples for Big PharmaThe American Society of Clinical Oncology promised a rating scale forcancer drugs--and now, it has delivered. Let the blowback begin. The drug scorecard, published in theJournal of Clinical Oncology,2015/6/24
-
Mylan CFO jetting off to Israel for stock exchange meeting: ReutersMylan ($MYL) is sending its CFO, John Sheehan, on the road in Israel. That's the home country of its spurned suitor Teva ($TEVA), but it's also one place where its takeover target Perrigo ($PRGO) is p2015/6/24
-
Top-spending pharma advertisers for 2016: J&J, Pfizer, Roche and NovartisPharma ad budgets may be set to dip overall in 2016, but the industry's big spenders will still be shelling out $2 billion each--or more--to promote their drugs, according to an annual spending study.2015/6/23
-
Generics maker Alvogen eyes faster growth after CVC-led buyoutIn the latest bit of pharma M&A, a group of investment funds teamed up to buy generics makerAlvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, i2015/6/23
-
U.S. court nixes Teva's Copaxone patent--againIt's been a long legal road forCopaxone, and one that took yet another turn Thursday as the U.S. Court of Appeals struck down the drug's patent for the second time. In January, the U.S. Supre2015/6/19
-
Valeant said to step up talks on potential $800M deal for Egypt's AmounLast month, reports said Valeant ($VRX) was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in th2015/6/18
-
Bad news for AbbVie: Humira copies expected to rack up biggest biosim salesHere's something AbbVie ($ABBV) doesn't want to hear: Industry watchers expect biosimilars for its top moneymakerHumirato be the most successful copycat biologics launched in the U.S. and Europe. Tha2015/6/17
-
Drug price hawk CVS Health and the case of the $44,000 nutrition supplementCVS Health ($CVS) may be staring down pricey hep C drugs and forthcoming PCSK9 meds, but capsules of powdered resveratrol? Not so much. The pharmacy benefits manager recently approved a $44,000 claim2015/6/17